'Ifn rbv' presentation slideshows

Chronic Hepatitis C and Project ECHO State of Affairs Spring 2013

Chronic Hepatitis C and Project ECHO State of Affairs Spring 2013. 68 th Annual Ogden Surgical-Medical Society Conference May 15, 2013 Terry Box, MD. Disclosures. Research funding: Abbott, Boehringer-Ingelheim, Bristol Meyers Squibb, Gilead, Idenix, Merck, Roche, Salix, Sundise

751 views • 63 slides

627 views • 46 slides

Hepatitis-C and HIV

Hepatitis-C and HIV. Michael T. Wong, MD Assistant Professor of Medicine, Harvard Medical School Division of Infectious Diseases, Beth Israel Deaconess Medical Center. HCV Primarily through blood and blood products, IDU

629 views • 46 slides

How Will New HCV Therapies Overcome the Challenges of Current Regimens?

How Will New HCV Therapies Overcome the Challenges of Current Regimens?. Jordan J. Feld, MD, MPH Assistant Professor of Medicine University of Toronto Hepatologist Toronto Western Hospital Liver Centre McLaughlin-Rotman Centre for Global Health Toronto, Ontario, Canada.

499 views • 38 slides

How Will New HCV Therapies Overcome the Challenges of Current Regimens?

How Will New HCV Therapies Overcome the Challenges of Current Regimens?. Jordan J. Feld, MD, MPH Assistant Professor of Medicine University of Toronto Hepatologist Toronto Western Hospital Liver Centre McLaughlin-Rotman Centre for Global Health Toronto, Ontario, Canada.

502 views • 38 slides

Strategic Applications of HCV Guidelines: Putting Protease Inhibitors into Practice

Strategic Applications of HCV Guidelines: Putting Protease Inhibitors into Practice. Jeff Allen, MD, FAAFP Chief of Health Programs, FBOP Michelle Williams, PharmD Lieutenant, USPHS Hepatitis/HIV Program Manager, FBOP Newton Kendig , MD RADM, Assistant Surgeon General, USPHS

435 views • 34 slides

New Anti-HCV Drugs Other Drugs?

580 views • 27 slides

?????????

???????????????. ?????????. ?????????. Frequent curability of diverse populations without IFN. IFN-free DAA combinations (GT1). Ribavirin. Suppression of HCV with DAA combination (PI + NI). Potential approval of other DAAs with IFN (eg, faldaprevir). Proof of concept for DAA (PI).

279 views • 26 slides

How to manage G1 relapsers and non-responders

How to manage G1 relapsers and non-responders. George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece. Case 1 - AM. 01/2008

357 views • 23 slides